Lck Inhibitor

CAS : 213743-31-8

Ref. 3D-NIA74331

Informations sur le produit

• Nom: Lck Inhibitor
• Synonymes: 7-Cyclopentyl-5-(4-phenoxy)phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine, 7H-pyrrolo[2,3-d]pyrimidin-4-amine, 7-cyclopentyl-5-(4-phenoxyphenyl)-, Kin 001-51, Rk 24466

Description

Lck inhibitor is a small-molecule drug that inhibits the enzyme Lck, which is a tyrosine kinase. It has been shown to be effective in reducing inflammation and preventing the formation of atherosclerotic plaques by inhibiting the activation of cells that promote inflammation and the production of inflammatory mediators. Dasatinib has also been shown to inhibit human CD4+ T-cells, hydrogen bond formation, and kinase selectivity. This drug is selective for Lck over other tyrosine kinases, such as Bcr/Abl or Src family members.
Dasatinib can be used for sample preparation before analysis with flow cytometry or immunohistochemistry because it does not interfere with these techniques. This drug is rapidly absorbed from the gastrointestinal tract after oral administration and excreted via urine. The pharmacokinetic properties of this drug are similar in humans and mice.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 370.45 g/mol
• Formule: C₂₃H₂₂N₄O
• Degré de pureté: Min. 95%